Financials data is unavailable for this security.
View more
Year on year Bliss GVS Pharma Ltd grew net income 6.49% from 708.59m to 754.54m despite relatively flat revenues.
| Gross margin | 51.81% |
|---|---|
| Net profit margin | 11.24% |
| Operating margin | 13.16% |
| Return on assets | -- |
|---|---|
| Return on equity | -- |
| Return on investment | -- |
More ▼
Cash flow in INRView more
In 2024, cash reserves at Bliss GVS Pharma Ltd fell by 14.16m. However, the company earned 1.52bn from its operations for a Cash Flow Margin of 19.79%. In addition the company used 1.33bn on investing activities and also paid 208.93m in financing cash flows.
| Cash flow per share | 10.98 |
|---|---|
| Price/Cash flow per share | 11.20 |
| Book value per share | -- |
|---|---|
| Tangible book value per share | -- |
More ▼
Balance sheet in INRView more
| Current ratio | -- |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | -- |
|---|---|
| Total debt/total capital | -- |
More ▼
Growth rates in INR
Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items increased 5.89%. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked below the industry average relative to its peers.
| Div yield(5 year avg) | 0.56% |
|---|---|
| Div growth rate (5 year) | -12.94% |
| Payout ratio (TTM) | 6.40% |
| EPS growth(5 years) | -9.92 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 35.13 |
More ▼
